Overview

A Study of LY3209590 in Participants With Type 1 Diabetes

Status:
Completed
Trial end date:
2021-10-01
Target enrollment:
Participant gender:
Summary
The reason for this study is to see if the study drug LY3209590 is safe and effective in participants with type 1 diabetes.
Phase:
Phase 2
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Insulin